Results 161 to 170 of about 26,261 (211)

Glucagon-Like Peptide-1 Receptor Agonist Use Does Not Impact Spine Surgery Outcomes: A Systematic Review and Meta-Analysis. [PDF]

Global Spine J
Ibrahim S, Durrani A, Ibrahim MT, Kuttner N, Glivar P, Singh VK, Yu E.   +6 more
europepmc   +1 more source

Estimating the excess expenditures associated with glucagon-like peptide-1 receptor agonist use among adults with diabetes in the United States. [PDF]

J Manag Care Spec Pharm
Akpan N, Zhou B, Rasu RS, Sambamoorthi U.   +3 more
europepmc   +1 more source

Patients on Long-Term Preoperative Glucagon-Like Peptide-1 Receptor Agonist Therapy Show Significant Reductions in Postoperative Complications After Elective Laminectomy in Overweight Adults: A Propensity-Matched Study. [PDF]

Int J Spine Surg
Wahid M, Zaidi Z, Isa S, Alshaikhsalama Y, Aoun SG.   +4 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Order Fills and Out-of-Pocket Costs by Race, Ethnicity, and Indication.

JAMA Health Forum
Sarpatwari A, Soto MJ, Ganguli I, Sloan CE, Goss F, Sinaiko AD.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucagon-Like Peptide-1 Receptor Agonists

Reactions Weekly
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Heather P. Whitley, Jennifer M. Trujillo
  +11 more sources

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Obesity and Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti, Francesco, Branca, Jeremy, Farrar   +2 more
openaire   +2 more sources

Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry

Journal of Clinical Psychopharmacology
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire   +3 more sources

Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses the health benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs); summarizes the clinical, policy, and equity implications of GLP-1 RA discontinuation; and calls for the identification and implementation of strategies to improve long-term adherence to GLP-1 RA therapy.
Sadiya S, Khan, Chiadi E, Ndumele, Dhruv S, Kazi   +2 more
openaire   +2 more sources